Urinary Tract Infections in Kidney Transplant Recipients (URIKIT)

Primary Outcome Measures:

• Assessment of UTI due to MDR bacteria [ Time Frame: Day 0 to 2 years ]
  Proportion of MDR bacteria compared to other bacteria found in urinalysis of symptomatic KIT patients
  
  

Secondary Outcome Measures:

• Epidemiology of UTI in KIT recipients [ Time Frame: Day 0 to 2 years ]
  Frequency of each bacteria or yeasts responsible for UTI
  
  
• Risk factors for MDR UTI [ Time Frame: Day 0 to 2 years ]
  Comparison of demographic and clinical characteristic of patients who develop an MDR versus a non-MDR UTI
  
  
• Carbapenem use to treat UTI [ Time Frame: Day 0 to 2 years ]
  Proportion of patients who received carbapenem for UTI treatment
  
  
• Coherence between antibiotic protocol and treatment received to treat UTI [ Time Frame: Day 0 to 2 years ]
  Proportion of patients who received carbapenem while responsible bacteria was susceptible to other antibiotics
  
  
• UTI relapse frequency [ Time Frame: Day 0 to 2 years ]
  Proportion of patients with at least one relaspe of UTI with the same bacteria
  
  
• UTI recurrence frequency with a different micororganism [ Time Frame: Day 0 to 2 years ]
  Proportion of patients with more than one UTI during the study period
  
  
• Assessment of kidney function during the observation period [ Time Frame: Day 0 to 2 years ]
  Difference between the initial kidney function (MDRD) and the final kidney function at the end of the observation period
  
  
• Graft outcome [ Time Frame: Day 0 to 2 years ]
  Number of patients needed a dialysis
  
  
• Patients outcome [ Time Frame: Day 0 to 2 years ]
  Number of deaths
  
  

Intervention Details:

Other: No intervention
No intervention

The risk of UTI after a kidney transplantation is higher than in the general population. MDR bacteria, such as extended spectrum betalactamase (ESBL)-producing enterobacteriaceae or MDR Pseumomoas aeruginosa are emerging threats due to antibiotic selective pressure. Epidemiological data are mostly data from hospital laboratories that do not show a complete overview of the current situation. In addition, the different centers which participated to this study received before the beginning of the study a protocol to avoid carbapenem use. The main objective of this study is to assess the prevalence of MDR bacteria in an adult population of KIT recipients. Through this study, the management of UTI in KIT recipients will be improved. Data on bacteria or yeasts responsible for UTI (identification, resistance profile), antibiotic use, patients' outcome, and graft outcome will be collected.